Compare Novavax Inc (NVAX) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Teucrium Soybean Fund — how do they compare? Novavax Inc trades at $11.81 (market cap $1.82B), while Teucrium Soybean Fund trades at $27.42 (market cap $43.52M). The key difference: Novavax Inc is far larger — about 41.8× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is more actively traded (32,585 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Teucrium Soybean Fund for 23 Days on average.
| NVAX | SOYB | |
|---|---|---|
Market Cap | $1.82B | $43.52M |
Volume | 6,198,505 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $12.56 | $28.14 |
52-Week Low | $6.22 | $21.55 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
